Related Experiment Video
Updated: Jun 23, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Investigational drugs for neuroendocrine tumours
1University Hospital, Institution of Medical Sciences, Department of Endocrine Oncology, Uppsala SE-75185, Sweden. dan.granberg@medsci.uu.se
Background:
Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus. The majority are malignant. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization.
Objective:
To review and discuss new treatments for patients with metastatic NETs.
Method:
Review of the published literature during the last 5 years on treatment of patients with NETs.
Results/Conclusion:
Several new drugs with various mechanisms of action including cytotoxic drugs, tyrosine kinase receptor inhibitors and antiangiogenic drugs as well as radiolabelled substances have been introduced during recent years. Many of these compounds have shown promising results in patients with NETs.
Insights
New treatments for metastatic neuroendocrine tumours (NETs) show promise. Recent advancements include novel drugs targeting NETs, offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Endocrinology
Background:
- Neuroendocrine tumours (NETs) are typically slow-growing malignant neoplasms.
- Metastatic NETs are often treated with biotherapy, chemotherapy, or embolization.
Purpose of the Study:
- To review emerging therapeutic strategies for metastatic NETs.
- To discuss recent advancements in NETs treatment.
Main Methods:
- Literature review of studies published in the last five years.
- Focus on novel treatment modalities for neuroendocrine tumours.
Main Results:
- Several new drugs with diverse mechanisms of action have been introduced.
- These include cytotoxic drugs, tyrosine kinase receptor inhibitors, and antiangiogenic agents.
- Radiolabeled substances also represent a new treatment avenue.
Conclusions:
- New therapeutic agents demonstrate promising results in patients with NETs.
- These advancements offer expanded treatment options for metastatic neuroendocrine tumours.
